U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C18H20FN3O4.H2O
Molecular Weight 740.7503
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOFLOXACIN

SMILES

O.C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4.C[C@H]5COC6=C7N5C=C(C(O)=O)C(=O)C7=CC(F)=C6N8CCN(C)CC8

InChI

InChIKey=SUIQUYDRLGGZOL-RCWTXCDDSA-N
InChI=1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1

HIDE SMILES / InChI
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C18H20FN3O4
Molecular Weight 361.3675
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:30:28 UTC 2023
Edited
by admin
on Fri Dec 15 15:30:28 UTC 2023
Record UNII
6GNT3Y5LMF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVOFLOXACIN
MART.   ORANGE BOOK   USAN   USP-RS   VANDF  
USAN  
Official Name English
OFLOXACIN S-(-)-FORM HEMIHYDRATE [MI]
Common Name English
(-)-(S)-9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, HEMIHYDRATE
Common Name English
LEVOFLOXACIN [VANDF]
Common Name English
LEVOFLOXACIN HYDRATE [JAN]
Common Name English
LEVOFLOXACIN HYDRATE
JAN  
Common Name English
LEVOFLOXACIN [ORANGE BOOK]
Common Name English
CRAVIT
Brand Name English
LEVOFLOXACIN [USP MONOGRAPH]
Common Name English
VOLEQUIN
Brand Name English
QUINSAIR
Brand Name English
IQUIX
Brand Name English
QUIXIN
Brand Name English
LEVOFLOXACIN HEMIHYDRATE
WHO-DD  
Common Name English
LEVAQUIN
Brand Name English
RWJ-25213
Code English
TAVANIC
Brand Name English
LEVOFLOXACIN HEMIHYDRATE [EP MONOGRAPH]
Common Name English
L-OFLOXACIN
Common Name English
DR-3355
Code English
7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-HYDRATE (2:1), (S)-
Common Name English
LEVOFLOXACIN (AS HEMIHYDRATE)
Common Name English
Levofloxacin hemihydrate [WHO-DD]
Common Name English
OFLOXACIN, (S)-
Common Name English
LEVOFLOXACIN [USP-RS]
Common Name English
LEVOFLOXACIN [USAN]
Common Name English
NOFAXIN
Brand Name English
LEVOFLOXACIN [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC S01AE05
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-ATC A02BD10
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
NDF-RT N0000007606
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
FDA ORPHAN DRUG 253707
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-ATC J01MA12
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
LIVERTOX NBK548357
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
NDF-RT N0000175937
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
NCI_THESAURUS C795
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
EU-Orphan Drug EU/3/08/566
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-VATC QS01AE05
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-VATC QJ01RA05
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-ATC J01RA05
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
EMA ASSESSMENT REPORTS QUINSAIR (AUTHORIZED: CYSTIC FIBROSIS)
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-VATC QJ01MA12
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C1586
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
RS_ITEM_NUM
1362103
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
FDA UNII
6GNT3Y5LMF
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
DAILYMED
6GNT3Y5LMF
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
WIKIPEDIA
LEVOFLOXACIN
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
EPA CompTox
DTXSID60160533
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
DRUG CENTRAL
1569
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
CHEBI
63598
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
USAN
II-30
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
EVMPD
SUB21640
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
CAS
138199-71-0
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
MERCK INDEX
m8133
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
SMS_ID
100000091529
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
PUBCHEM
3033924
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
LACTMED
Levofloxacin
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
DRUG BANK
DB01137
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
RXCUI
82122
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL33
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
ROUTE OF ADMINISTRATION: ORAL AND INJECTION
BINDING
Structure of LEVOFLOXACIN ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of LEVOFLOXACIN ANHYDROUS
PARENT -> SALT/SOLVATE
Structure of LEVOFLOXACIN ANHYDROUS
ANHYDROUS->SOLVATE
Related Record Type Details
Structure of 9-DESFLUORO LEVOFLOXACIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(2-(METHYLAMINO)ETHYLAMINO)-7-OXO-7H-PYRIDO(1,2,3-DE)(1,4)BENZOXAZINE-6-CARBOXYLIC ACID, (S)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of OFLOXACIN, D-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9-DESFLUORO LEVOFLOXACIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DECARBOXYL OFLOXACIN, (S)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of LEVOFLOXACIN N-OXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of OFLOXACIN, D-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-DESMETHYL LEVOFLOXACIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-DESMETHYL LEVOFLOXACIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of LEVOFLOXACIN Q-ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LEVOFLOXACIN N-OXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LEVOFLOXACIN ETHYL ESTER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9-PIPERAZINO OFLOXACIN, (S)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(2-(METHYLAMINO)ETHYLAMINO)-7-OXO-7H-PYRIDO(1,2,3-DE)(1,4)BENZOXAZINE-6-CARBOXYLIC ACID, (S)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LEVOFLOXACIN Q-ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of LEVOFLOXACIN ANHYDROUS
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MIC PHARMACOKINETIC SUSCEPTIBILITY: RESISTANT

PATHOGEN: ENTEROBACTERIACEAE, E. FAECALIS, STAPHYLOCOCCUS SPECIES, P. AERUGINOSA, S. PNEUMONIAE, S. PYOGENES

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: ENTEROBACTERIACEAE, E. FAECALIS, STAPHYLOCOCCUS SPECIES, P. AERUGINOSA, H. INFLUENZAE, H. PARAINFLUENZAE, S. PNEUMONIAE, S. PYOGENES

Volume of Distribution PHARMACOKINETIC POPULATION: INFANTS ≥ 6 MONTHS, CHILDREN, AND ADOLESCENTS ≤ 16 YEARS

Biological Half-life PHARMACOKINETIC POPULATION: CHILDREN 12-16 YEARS

Biological Half-life PHARMACOKINETIC POPULATION: CHILDREN 5-10 YEARS

Tmax PHARMACOKINETIC
MIC PHARMACOKINETIC SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: YERSINIA PESTIS, BACILLUS ANTHRACIS

Biological Half-life PHARMACOKINETIC POPULATION: ADULTS WITH RENAL IMPAIRMENT (CrCL < 20 ML/MIN)

Biological Half-life PHARMACOKINETIC POPULATION: CHILDREN 10-12 YEARS

ORAL BIOAVAILABILITY PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

Biological Half-life PHARMACOKINETIC POPULATION: ADULTS WITH RENAL IMPAIRMENT (CrCL 20-49 ML/MIN)

Volume of Distribution PHARMACOKINETIC POPULATION: ADULTS

Biological Half-life PHARMACOKINETIC POPULATION: INFANTS ≥ 6 MONTHS AND CHILDREN ≤ 5 YEARS

Biological Half-life PHARMACOKINETIC POPULATION: ADULTS

MIC PHARMACOKINETIC SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN: ENTEROBACTERIACEAE, E. FAECALIS, STAPHYLOCOCCUS SPECIES, P. AERUGINOSA, S. PNEUMONIAE, S. PYOGENES

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966